UP!
 |
|
|
Type
|
Public |
|---|---|
| Traded as | NASDAQ: ANTH |
| Industry | Pharmaceuticals |
| Founded | 2004 |
| Headquarters | Hayward, California, U.S. |
|
Key people
|
Craig Thompson (President and CEO) |
| Website | Anthera.com |
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious conditions associated with cystic fibrosis, inflammation and autoimmune diseases. Liprotamase (Sollpura), Anthera’s leading drug candidate which is being developed for exocrine pancreatic insufficiency (EPI) is currently in Phase 3 clinical trials, and A-623 (Blisibimod) for the treatment of IgA nephropathy is currently in Phase 2 clinical trial.
July 2014, Anthera acquired Sollpura (Liprotamase) from Eli Lilly and Company. Sollpura is an investigational pancreatic enzyme replacement therapy (PERT) that uses three biotechnology-derived digestive enzymes intended to treat patients with endocrine pancreatic insufficiency as a result of cystic fibrosis and other diseases.
| 2016-07-08 | Initiated Coverage | HC Wainwright | Buy | $10.00 |
| 2016-06-30 | Reiterated Rating | Jefferies Group | Buy | |
| 2016-06-20 | Reiterated Rating | FBR & Co. | Hold | |
| 2016-06-20 | Reiterated Rating | FBR & Co | Hold | |
| 2016-06-09 | Reiterated Rating | Jefferies Group | Buy | |
| 2016-03-11 | Lower Price Target | Piper Jaffray | Overweight | $14.00 to $10.00 |
| 2016-03-11 | Lower Price Target | Piper Jaffray Cos. | Overweight | $14.00 to $10.00 |
| 2016-02-19 | Lower Price Target | Citigroup Inc. | $15.00 to $11.00 | |
| 2016-02-19 | Reiterated Rating | Jefferies Group | Buy | $12.00 to $9.00 |
| 2015-09-17 | Initiated Coverage | Citigroup Inc. | Buy | $15.00 |
| 2015-09-15 | Reiterated Rating | Piper Jaffray | Overweight | $14.00 |
| 2015-09-08 | Initiated Coverage | SunTrust | Buy | $14.00 |
| 2015-09-08 | Initiated Coverage | SunTrust Banks Inc. | Buy | $14.00 |
| 2015-05-20 | Upgrade | Citigroup Inc. | Neutral | |
| 2015-05-12 | Upgrade | Citigroup Inc. | Sell to Neutral | |
| 2015-03-30 | Boost Price Target | Piper Jaffray | $7.50 | |
| 2015-03-17 | Reiterated Rating | Jefferies Group | Buy | $18.00 to $12.00 |
| 2012-06-29 | Downgrade | Ascendiant Capital Markets | Buy to Neutral | $2.50 to $0.90 |
| 2012-06-28 | Downgrade | JMP Securities | Mkt Outperform to Mkt Perform | |
| 2012-06-13 | Initiated | JMP Securities | Mkt Outperform | $4 |
| 2012-06-04 | Initiated | Ascendiant Capital Markets | Buy | $2.50 |
| 2012-04-26 | Initiated | MLV & Co | Buy | $4.50 |
| 2012-03-12 | Reiterated | Canaccord Genuity | Buy | $13 to $6 |
| 2011-12-02 | Initiated | Collins Stewart | Buy | $13 |
| 2011-11-01 | Initiated | Deutsche Bank | Buy | $14 |
| 2011-08-01 | Downgrade | Wedbush | Outperform to Neutral | $9 to $7 |
| 2010-10-20 | Initiated | MP Advisors | Outperform | $9 |
| 2010-10-06 | Initiated | Wedbush | Outperform | $8 |
| 2016-07-08 | Initiated Coverage | HC Wainwright | Buy | $10.00 |
| 2016-06-30 | Reiterated Rating | Jefferies Group | Buy | |
| 2016-06-20 | Reiterated Rating | FBR & Co. | Hold | |
| 2016-06-20 | Reiterated Rating | FBR & Co | Hold | |
| 2016-06-09 | Reiterated Rating | Jefferies Group | Buy |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In ANTH 0 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| ORBIMED ADVISORS LLC | 32.85% (7462000) | AGLE / AMBI / ANTH / ATHX / BOLD / BONE / CRVS / CTIC / ICPT / KALA / LOXO / MRTX / OTIC / RLYP / ROKA / SIEN / SUPN / SYBX / XLRN / |
| VANTAGEPOINT VENTURE ASSOCIATES IV LLC | 23.59% (5357528) | ANTH / GCAP / WAGE / |
| Thompson David E. | 0.56% (128201) | ANTH / |
| LOWE CHRISTOPHER P. Chief Financial Officer & CBO | 0.48% (108915) | ANTH / HNSN / |
| HENNEY CHRISTOPHER S | 0.44% (100000) | ANTH / CYCC / ONTY / PRTA / |
| SOFINNOVA VENTURE PARTNERS VI L P | 0.20% (44969) | ANTH / OCRX / |
| HEALY JAMES | 0.14% (32443) | ANTH / DRTX / HPTX / ITMN / KBIO / |
| Hislop Colin Chief Medical Officer | 0.14% (31647) | ANTH / VSAR / |
| KILFOIL GEORGINA SVP, Prod. Dev. & Project Mngm | 0.13% (30035) | ANTH / |
| THOMPSON JOHN CRAIG President & COO | 0.09% (19848) | ANTH / TTPH / |
| TRUEX PAUL F President and CEO | 0.07% (16793) | ANTH / CBAY / |
| Mueller Brian | 0.04% (10000) | ANTH / BMRN / |
| DZIURZYNSKI BOGDAN | 0.04% (10000) | ANTH / DNDN / |
| ODINK DEBRA Chief Technology Officer | 0.03% (7896) | ANTH / |
| LIU MAY Chief Accounting Officer | 0.03% (7302) | ANTH / |
UM